Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its diosmectite, the Active Pharmaceutical Ingredient (API) in Simcere's branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the European Union countries.
Simcere has been manufacturing and marketing diosmectite API and formulation under the Biqi brand name for many years in China. Diosmectite is made from a natural mineral material and its formulation is the leading antidiarrheal drug in China and France. Simcere owns a high grade diosmectite mine in China.
"We are delighted that Simcere's diosmectite has passed EU-GMP inspection and been approved for sale in the EU," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "This is an important start in driving our international business."
Recycled food waste may be contaminated with pharmaceutical residues, research reveals